Brown Advisory Inc. Increases Stake in Kestra Medical Technologies, Ltd. $KMTS

Brown Advisory Inc. increased its position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 34.1% in the 4th quarter, HoldingsChannel reports. The fund owned 1,688,356 shares of the company’s stock after purchasing an additional 428,996 shares during the period. Brown Advisory Inc.’s holdings in Kestra Medical Technologies were worth $44,775,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies in the 4th quarter worth about $31,000. China Universal Asset Management Co. Ltd. purchased a new position in Kestra Medical Technologies during the 3rd quarter valued at about $48,000. BNP Paribas Financial Markets grew its holdings in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in Kestra Medical Technologies during the 4th quarter valued at about $72,000. Finally, Brown Brothers Harriman & Co. grew its holdings in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on KMTS. The Goldman Sachs Group reduced their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $27.40.

Kestra Medical Technologies Stock Performance

Shares of KMTS opened at $20.41 on Tuesday. The company has a market cap of $1.19 billion, a PE ratio of -5.15 and a beta of 0.83. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average price of $20.71 and a 200-day moving average price of $23.03. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm’s quarterly revenue was up 62.7% on a year-over-year basis. As a group, equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider owned 334,786 shares in the company, valued at approximately $7,017,114.56. This trade represents a 4.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.60% of the company’s stock.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.